Disease manifestations by antibody status
| ANA (N=2085) | Anti-Scl-70 (N=854) | Anti-RNA Pol 3 (N=86) | ACA (N=775) | Anti-U1 RNP (N=120) | Anti-U3 RNP (N=39) | |
|---|---|---|---|---|---|---|
| Lung fibrosis, n/N (%) (95% CI) | 873/2085 (41.9) (39.7 to 44.0) | 531/854 (62.2) (58.8 to 65.4) | 36/86 (41.9) (31.3 to 53.0) | 173/775 (22.3) (19.4 to 25.4) | 50/120 (41.7) (32.7 to 51.0) | 16/39 (41.0) (25.6 to 57.9) |
| PAH, n/N (%) (95% CI) | 307/2085 (14.7) (13.2 to 16.3) | 133/854 (15.6) (13.2 to 18.2) | 12/86 (14.0) (7.4 to 23.1) | 120/775 (15.5) (13.0 to 18.2) | 19/120 (15.8) (9.8 to 23.6) | 9/39 (23.1) (11.1 to 39.3) |
| Kidney manifestations, n/N (%) (95% CI) | 105/2085 (5.0) (4.1 to 6.1) | 43/854 (5.0) (3.7 to 6.7) | 7/86 (8.1) (3.3 to 16.1) | 26/775 (3.4) (2.2 to 4.9) | 10/120 (8.3) (4.1 to 14.8) | 5/39 (12.8) (4.3 to 27.4) |
| Gastrointestinal manifestations, n/N (%) (95% CI) | 1192/2085 (57.2) (55.0 to 59.3) | 498/854 (58.3) (56.4 to 63.9) | 51/86 (59.3) (47.9 to 70.8) | 440/775 (56.8) (53.2 to 60.3) | 63/120 (52.5) (43.2 to 61.7) | 15/39 (38.5) (23.4 to 55.4) |
| Heart manifestations, n/N (%) (95% CI) | 220/2085 (10.6) (9.3 to 12.0) | 105/854 (12.3) (10.2 to 14.7) | 6/86 (7.0) (2.6 to 14.6) | 47/775 (6.1) (4.5 to 8.0) | 16/120 (13.3) (7.8 to 20.7) | 3/39 (7.7) (1.6 to 20.9) |
The denominator N varies according to the number of available observations.
* Antibody subsets are not mutually exclusive: one patient can have several antibodies and therefore contribute to several groups.
ACA, anticentromere antibodies; ANA, antinuclear antibodies; anti-Scl-70, anti-scleroderma-70 antibodies; anti-RNA Pol 3, anti-RNA polymerase 3; anti-U1 RNP, anti-U1 ribonucleoprotein; anti-U3 RNP, anti-U3 ribonucleoprotein; PAH, pulmonary arterial hypertension.